Coave Therapeutics and Théa Open Innovation sign exclusive licensing, co-development and commercialization agreement for Europe for CTx-PDE6b, a novel gene therapy candidate in retinitis pigmentosa ...Middle East

PARIS, Sept. 16, 2021 /PRNewswire/ -- Coave Therapeutics ('Coave'), a clinical-stage biotechnology company focused on developing life-changing gene therapies in rare Ocular and CNS (Central Nervous System) diseases, has entered into an exclusive licensing, co-development and...

Hence then, the article about coave therapeutics and thea open innovation sign exclusive licensing co development and commercialization agreement for europe for ctx pde6b a novel gene therapy candidate in retinitis pigmentosa was published today ( Thursday 16/09/2021 - 09:30 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Coave Therapeutics and Théa Open Innovation sign exclusive licensing, co-development and commercialization agreement for Europe for CTx-PDE6b, a novel gene therapy candidate in retinitis pigmentosa )

Also on site :

• What to Know About Allegations of Excessive Drinking by FBI Director Kash Patel
• Gunman opens fire and seizes supermarket in Kiev (VIDEOS)
• Trump rolls out Joe Rogan for White House psychedelics announcement and jokes he’d like some for anxiety